1557 related articles for article (PubMed ID: 33648563)
1. Effect of early treatment with polyvalent immunoglobulin on acute respiratory distress syndrome associated with SARS-CoV-2 infections (ICAR trial): study protocol for a randomized controlled trial.
Mazeraud A; Gonçalves B; Aegerter P; Mancusi L; Rieu C; Bozza F; Sylla K; Siami S; Sharshar T
Trials; 2021 Feb; 22(1):170. PubMed ID: 33648563
[TBL] [Abstract][Full Text] [Related]
2. Intravenous immunoglobulins in patients with COVID-19-associated moderate-to-severe acute respiratory distress syndrome (ICAR): multicentre, double-blind, placebo-controlled, phase 3 trial.
Mazeraud A; Jamme M; Mancusi RL; Latroche C; Megarbane B; Siami S; Zarka J; Moneger G; Santoli F; Argaud L; Chillet P; Muller G; Bruel C; Asfar P; Beloncle F; Reignier J; Vinsonneau C; Schimpf C; Amour J; Goulenok C; Lemaitre C; Rohaut B; Mateu P; De Rudnicki S; Mourvillier B; Declercq PL; Schwebel C; Stoclin A; Garnier M; Madeux B; Gaudry S; Bailly K; Lamer C; Aegerter P; Rieu C; Sylla K; Lucas B; Sharshar T
Lancet Respir Med; 2022 Feb; 10(2):158-166. PubMed ID: 34774185
[TBL] [Abstract][Full Text] [Related]
3. Rationale and design of the PRAETORIAN-COVID trial: A double-blind, placebo-controlled randomized clinical trial with valsartan for PRevention of Acute rEspiraTORy dIstress syndrome in hospitAlized patieNts with SARS-COV-2 Infection Disease.
Gommans DHF; Nas J; Pinto-Sietsma SJ; Koop Y; Konst RE; Mensink F; Aarts GWA; Konijnenberg LSF; Cortenbach K; Verhaert DVM; Thannhauser J; Mol JQ; Rooijakkers MJP; Vos JL; van Rumund A; Vart P; Hassing RJ; Cornel JH; de Jager CPC; van den Heuvel MM; van der Hoeven HG; Verbon A; Pinto YM; van Royen N; van Kimmenade RRJ; ; de Leeuw PW; van Agtmael MA; Bresser P; ; van Gilst WH; Vonk-Noordergraaf A; Tijssen JGP; ; van Royen N; de Jager CPC; van den Heuvel MM; van der Hoeven HG; Verbon A; Pinto YM; van Kimmenade RRJ
Am Heart J; 2020 Aug; 226():60-68. PubMed ID: 32512291
[TBL] [Abstract][Full Text] [Related]
4. Effect of Dexamethasone on Days Alive and Ventilator-Free in Patients With Moderate or Severe Acute Respiratory Distress Syndrome and COVID-19: The CoDEX Randomized Clinical Trial.
Tomazini BM; Maia IS; Cavalcanti AB; Berwanger O; Rosa RG; Veiga VC; Avezum A; Lopes RD; Bueno FR; Silva MVAO; Baldassare FP; Costa ELV; Moura RAB; Honorato MO; Costa AN; Damiani LP; Lisboa T; Kawano-Dourado L; Zampieri FG; Olivato GB; Righy C; Amendola CP; Roepke RML; Freitas DHM; Forte DN; Freitas FGR; Fernandes CCF; Melro LMG; Junior GFS; Morais DC; Zung S; Machado FR; Azevedo LCP;
JAMA; 2020 Oct; 324(13):1307-1316. PubMed ID: 32876695
[TBL] [Abstract][Full Text] [Related]
5. The INVENT COVID trial: a structured protocol for a randomized controlled trial investigating the efficacy and safety of intravenous imatinib mesylate (Impentri®) in subjects with acute respiratory distress syndrome induced by COVID-19.
Atmowihardjo L; Schippers JR; Bartelink IH; Bet PM; van Rein N; Purdy K; Cavalla D; Comberiati V; McElroy A; Snape SD; Bogaard HJ; Heunks L; Juffermans N; Schultz M; Tuinman PR; Bos LDJ; Aman J
Trials; 2022 Feb; 23(1):158. PubMed ID: 35172891
[TBL] [Abstract][Full Text] [Related]
6. A prospective, randomized, controlled study assessing vagus nerve stimulation using the gammaCore®-Sapphire device for patients with moderate to severe CoViD-19 Respiratory Symptoms (SAVIOR): A structured summary of a study protocol for a randomised controlled trial".
Tornero C; Vallejo R; Cedeño D; Orduña J; Pastor E; Belaouchi M; Escamilla B; Laredo M; Del Mar Garzando M
Trials; 2020 Jun; 21(1):576. PubMed ID: 32586395
[TBL] [Abstract][Full Text] [Related]
7. Open-label randomized controlled trial of ultra-low tidal ventilation without extracorporeal circulation in patients with COVID-19 pneumonia and moderate to severe ARDS: study protocol for the VT4COVID trial.
Richard JC; Yonis H; Bitker L; Roche S; Wallet F; Dupuis C; Serrier H; Argaud L; Thiery G; Delannoy B; Pommier C; Abraham P; Muller M; Aubrun F; Sigaud F; Rigault G; Joffredo E; Mezidi M; Terzi N; Rabilloud M
Trials; 2021 Oct; 22(1):692. PubMed ID: 34635128
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic iloprost for the treatment of acute respiratory distress syndrome (ARDS) (the ThIlo trial): a prospective, randomized, multicenter phase II study.
Haeberle H; Prohaska S; Martus P; Straub A; Zarbock A; Marx G; Zago M; Giera M; Koeppen M; Rosenberger P
Trials; 2020 Mar; 21(1):242. PubMed ID: 32131881
[TBL] [Abstract][Full Text] [Related]
9. Clinical outcomes of intravenous immunoglobulin therapy in COVID-19 related acute respiratory distress syndrome: a retrospective cohort study.
Ali HS; Elshafei MS; Saad MO; Mitwally HA; Al Wraidat M; Aroos A; Shaikh N; Ananthegowda DC; Abdelaty MA; George S; Nashwan AJ; Mohamed AS; Khatib MY
BMC Pulm Med; 2021 Nov; 21(1):354. PubMed ID: 34743710
[TBL] [Abstract][Full Text] [Related]
10. Azithromycin added to hydroxychloroquine for patients admitted to intensive care due to coronavirus disease 2019 (COVID-19)-protocol of randomised controlled trial AZIQUINE-ICU.
Duška F; Waldauf P; Halačová M; Zvoníček V; Bala J; Balík M; Beneš J; Klementová O; Kozáková I; Kubricht V; Le Roy A; Vymazal T; Řehořová V; Černý V;
Trials; 2020 Jul; 21(1):631. PubMed ID: 32641163
[TBL] [Abstract][Full Text] [Related]
11. COVID-19-associated ARDS treated with DEXamethasone (CoDEX): study design and rationale for a randomized trial.
Tomazini BM; Maia IS; Bueno FR; Silva MVAO; Baldassare FP; Costa ELV; Moura RAB; Honorato MO; Costa AN; Cavalcanti AB; Rosa RG; Avezum Á; Veiga VC; Lopes RD; Damiani LP; Machado FR; Berwanger O; Azevedo LCP;
Rev Bras Ter Intensiva; 2020; 32(3):354-362. PubMed ID: 33053024
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of dexamethasone treatment for patients with the acute respiratory distress syndrome caused by COVID-19: study protocol for a randomized controlled superiority trial.
Villar J; Añón JM; Ferrando C; Aguilar G; Muñoz T; Ferreres J; Ambrós A; Aldecoa C; Suárez-Sipmann F; Thorpe KE; Jüni P; Slutsky AS;
Trials; 2020 Aug; 21(1):717. PubMed ID: 32799933
[TBL] [Abstract][Full Text] [Related]
13. Mesenchymal stem cells derived from perinatal tissues for treatment of critically ill COVID-19-induced ARDS patients: a case series.
Hashemian SR; Aliannejad R; Zarrabi M; Soleimani M; Vosough M; Hosseini SE; Hossieni H; Keshel SH; Naderpour Z; Hajizadeh-Saffar E; Shajareh E; Jamaati H; Soufi-Zomorrod M; Khavandgar N; Alemi H; Karimi A; Pak N; Rouzbahani NH; Nouri M; Sorouri M; Kashani L; Madani H; Aghdami N; Vasei M; Baharvand H
Stem Cell Res Ther; 2021 Jan; 12(1):91. PubMed ID: 33514427
[TBL] [Abstract][Full Text] [Related]
14. Use of Intravenous Immunoglobulin (Prevagen or Octagam) for the Treatment of COVID-19: Retrospective Case Series.
Herth FJF; Sakoulas G; Haddad F
Respiration; 2020; 99(12):1145-1153. PubMed ID: 33316806
[TBL] [Abstract][Full Text] [Related]
15. A parallel-group, multicenter randomized, double-blinded, placebo-controlled, phase 2/3, clinical trial to test the efficacy of pyridostigmine bromide at low doses to reduce mortality or invasive mechanical ventilation in adults with severe SARS-CoV-2 infection: the Pyridostigmine In Severe COvid-19 (PISCO) trial protocol.
Fragoso-Saavedra S; Iruegas-Nunez DA; Quintero-Villegas A; García-González HB; Nuñez I; Carbajal-Morelos SL; Audelo-Cruz BM; Arias-Martínez S; Caro-Vega Y; Calva JJ; Luqueño-Martínez V; González-Duarte A; Crabtree-Ramírez B; Crispín JC; Sierra-Madero J; Belaunzarán-Zamudio PF; Valdés-Ferrer SI
BMC Infect Dis; 2020 Oct; 20(1):765. PubMed ID: 33066761
[TBL] [Abstract][Full Text] [Related]
16. Treatment of COVID-19-associated ARDS with mesenchymal stromal cells: a multicenter randomized double-blind trial.
Monsel A; Hauw-Berlemont C; Mebarki M; Heming N; Mayaux J; Nguekap Tchoumba O; Diehl JL; Demoule A; Annane D; Marois C; Demeret S; Weiss E; Voiriot G; Fartoukh M; Constantin JM; Mégarbane B; Plantefève G; Malard-Castagnet S; Burrel S; Rosenzwajg M; Tchitchek N; Boucher-Pillet H; Churlaud G; Cras A; Maheux C; Pezzana C; Diallo MH; Ropers J; Menasché P; Larghero J;
Crit Care; 2022 Feb; 26(1):48. PubMed ID: 35189925
[TBL] [Abstract][Full Text] [Related]
17. SCARLET (Supplemental Citicoline Administration to Reduce Lung injury Efficacy Trial): study protocol for a single-site, double-blinded, placebo-controlled, and randomized Phase 1/2 trial of i.v. citicoline (CDP-choline) in hospitalized SARS CoV-2-infected patients with hypoxemic acute respiratory failure.
Pannu S; Exline MC; Bednash JS; Englert JA; Diaz P; Bartlett A; Brock G; Wu Q; Davis IC; Crouser ED
Trials; 2024 May; 25(1):328. PubMed ID: 38760804
[TBL] [Abstract][Full Text] [Related]
18. Early spontaneous breathing for acute respiratory distress syndrome in individuals with COVID-19.
Hohmann F; Wedekind L; Grundeis F; Dickel S; Frank J; Golinski M; Griesel M; Grimm C; Herchenhahn C; Kramer A; Metzendorf MI; Moerer O; Olbrich N; Thieme V; Vieler A; Fichtner F; Burns J; Laudi S
Cochrane Database Syst Rev; 2022 Jun; 6(6):CD015077. PubMed ID: 35767435
[TBL] [Abstract][Full Text] [Related]
19. A multicenter, open-label, randomized, proof-of-concept phase II clinical trial to assess the efficacy and safety of icatibant in patients infected with SARS-CoV-2 (COVID-19) and admitted to hospital units without invasive mechanical ventilation: study protocol (ICAT-COVID).
Malchair P; Otero A; Giol J; Solanich X; Carnaval T; Fernández-Nistal A; Sánchez-Gabriel A; Montoto C; Lleonart R; Videla S;
Trials; 2022 Apr; 23(1):303. PubMed ID: 35413921
[TBL] [Abstract][Full Text] [Related]
20. Using BCG vaccine to enhance non-specific protection of health care workers during the COVID-19 pandemic: A structured summary of a study protocol for a randomised controlled trial in Denmark.
Madsen AMR; Schaltz-Buchholzer F; Benfield T; Bjerregaard-Andersen M; Dalgaard LS; Dam C; Ditlev SB; Faizi G; Johansen IS; Kofoed PE; Kristensen GS; Loekkegaard ECL; Mogensen CB; Mohamed L; Ostenfeld A; Oedegaard ES; Soerensen MK; Wejse C; Jensen AKG; Nielsen S; Krause TG; Netea MG; Aaby P; Benn CS
Trials; 2020 Sep; 21(1):799. PubMed ID: 32943115
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
